Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo

Hepatocellular carcinoma results in a high risk of second primary malignancies and has prominent morbidity and mortality. There is a lack of effective treatment and prognosis is poor. Therefore, effective drugs need to be discovered. Carrimycin is a 16-member macrolide antibiotic with anticancer act...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yong Jin, Hong Xiang Zuo, Ming Yue Li, Zhi Hong Zhang, Yue Xing, Jing Ying Wang, Juan Ma, Gao Li, Hongxin Piao, Puqing Gu, Xuejun Jin
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	carrimycin monomeric isovalerylspiramycin I hepatocellular carcinoma anti-tumor in vitro in vivo Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/ae98af237b344c95b9cb4df31a9d8bf2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ae98af237b344c95b9cb4df31a9d8bf2
record_format	dspace
spelling	oai:doaj.org-article:ae98af237b344c95b9cb4df31a9d8bf22021-12-01T07:38:14ZAnti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo1663-981210.3389/fphar.2021.774231https://doaj.org/article/ae98af237b344c95b9cb4df31a9d8bf22021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.774231/fullhttps://doaj.org/toc/1663-9812Hepatocellular carcinoma results in a high risk of second primary malignancies and has prominent morbidity and mortality. There is a lack of effective treatment and prognosis is poor. Therefore, effective drugs need to be discovered. Carrimycin is a 16-member macrolide antibiotic with anticancer activity, and monomeric isovalerylspiramycin I is a main component. The aim of this study was to determine the anti-tumor effects of carrimycin and monomeric isovalerylspiramycin I on hepatocellular carcinoma through in vivo and in vitro experiments. In vitro, changes in cellular proliferation, migration, invasion, and apoptosis were analyzed by MTT, colony formation, EdU labeling, wound-healing, matrigel transwell invasion, and flow cytometric assays using SK-Hep1, Hep3B, SNU-354, SNU-387 hepatocellular carcinoma cell lines. Western blotting and RT-PCR were used to detect the effects of carrimycin and monomeric isovalerylspiramycin I on the expression levels of vascular endothelial growth factor (VEGF) and programmed death ligand 1 (PD-L1). Nude mice were subcutaneously transplanted with SK-Hep1 cells or C57BL/6J mice were orthotopically transplanted with hepatocarcinoma H22 cells. Tumor volume, pathological changes in tumor tissues, and the concentration of VEGF in mouse serum were measured after treatments. Carrimycin and monomeric isovalerylspiramycin I dose-dependently inhibited hepatocellular carcinoma cell viability, colony formation, and DNA replication. These agents markedly suppressed migration and invasion and promoted apoptosis of the cell lines. Western blotting and RT-PCR demonstrated that carrimycin and monomeric isovalerylspiramycin I reduced VEGF and PD-L1 protein and mRNA levels in a dose-dependent manner. In vivo studies further confirmed that carrimycin and monomeric isovalerylspiramycin I could significantly inhibit tumor growth, tumor histopathological alterations, and the concentration of VEGF in both mouse tumor models. These results show that carrimycin and monomeric isovalerylspiramycin I promoted apoptosis and inhibited proliferation, migration, and invasion of hepatocellular carcinoma cells. Therefore, our discovery suggests anti-tumor capacity for carrimycin and monomeric isovalerylspiramycin I and provides data on potential new drugs for inhibiting hepatocellular carcinoma.Yong JinHong Xiang ZuoMing Yue LiZhi Hong ZhangYue XingJing Ying WangJuan MaGao LiHongxin PiaoPuqing GuXuejun JinFrontiers Media S.A.articlecarrimycinmonomeric isovalerylspiramycin Ihepatocellular carcinomaanti-tumorin vitroin vivoTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	carrimycin monomeric isovalerylspiramycin I hepatocellular carcinoma anti-tumor in vitro in vivo Therapeutics. Pharmacology RM1-950
spellingShingle	carrimycin monomeric isovalerylspiramycin I hepatocellular carcinoma anti-tumor in vitro in vivo Therapeutics. Pharmacology RM1-950 Yong Jin Hong Xiang Zuo Ming Yue Li Zhi Hong Zhang Yue Xing Jing Ying Wang Juan Ma Gao Li Hongxin Piao Puqing Gu Xuejun Jin Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo
description	Hepatocellular carcinoma results in a high risk of second primary malignancies and has prominent morbidity and mortality. There is a lack of effective treatment and prognosis is poor. Therefore, effective drugs need to be discovered. Carrimycin is a 16-member macrolide antibiotic with anticancer activity, and monomeric isovalerylspiramycin I is a main component. The aim of this study was to determine the anti-tumor effects of carrimycin and monomeric isovalerylspiramycin I on hepatocellular carcinoma through in vivo and in vitro experiments. In vitro, changes in cellular proliferation, migration, invasion, and apoptosis were analyzed by MTT, colony formation, EdU labeling, wound-healing, matrigel transwell invasion, and flow cytometric assays using SK-Hep1, Hep3B, SNU-354, SNU-387 hepatocellular carcinoma cell lines. Western blotting and RT-PCR were used to detect the effects of carrimycin and monomeric isovalerylspiramycin I on the expression levels of vascular endothelial growth factor (VEGF) and programmed death ligand 1 (PD-L1). Nude mice were subcutaneously transplanted with SK-Hep1 cells or C57BL/6J mice were orthotopically transplanted with hepatocarcinoma H22 cells. Tumor volume, pathological changes in tumor tissues, and the concentration of VEGF in mouse serum were measured after treatments. Carrimycin and monomeric isovalerylspiramycin I dose-dependently inhibited hepatocellular carcinoma cell viability, colony formation, and DNA replication. These agents markedly suppressed migration and invasion and promoted apoptosis of the cell lines. Western blotting and RT-PCR demonstrated that carrimycin and monomeric isovalerylspiramycin I reduced VEGF and PD-L1 protein and mRNA levels in a dose-dependent manner. In vivo studies further confirmed that carrimycin and monomeric isovalerylspiramycin I could significantly inhibit tumor growth, tumor histopathological alterations, and the concentration of VEGF in both mouse tumor models. These results show that carrimycin and monomeric isovalerylspiramycin I promoted apoptosis and inhibited proliferation, migration, and invasion of hepatocellular carcinoma cells. Therefore, our discovery suggests anti-tumor capacity for carrimycin and monomeric isovalerylspiramycin I and provides data on potential new drugs for inhibiting hepatocellular carcinoma.
format	article
author	Yong Jin Hong Xiang Zuo Ming Yue Li Zhi Hong Zhang Yue Xing Jing Ying Wang Juan Ma Gao Li Hongxin Piao Puqing Gu Xuejun Jin
author_facet	Yong Jin Hong Xiang Zuo Ming Yue Li Zhi Hong Zhang Yue Xing Jing Ying Wang Juan Ma Gao Li Hongxin Piao Puqing Gu Xuejun Jin
author_sort	Yong Jin
title	Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo
title_short	Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo
title_full	Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo
title_fullStr	Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo
title_full_unstemmed	Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo
title_sort	anti-tumor effects of carrimycin and monomeric isovalerylspiramycin i on hepatocellular carcinoma in vitro and in vivo
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/ae98af237b344c95b9cb4df31a9d8bf2
work_keys_str_mv	AT yongjin antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT hongxiangzuo antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT mingyueli antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT zhihongzhang antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT yuexing antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT jingyingwang antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT juanma antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT gaoli antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT hongxinpiao antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT puqinggu antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo AT xuejunjin antitumoreffectsofcarrimycinandmonomericisovalerylspiramycinionhepatocellularcarcinomainvitroandinvivo
_version_	1718405434074726400

Anti-Tumor Effects of Carrimycin and Monomeric Isovalerylspiramycin I on Hepatocellular Carcinoma in Vitro and in Vivo

Ejemplares similares